Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)’s shares have oscillated between a high of $4.63% and a low of $233.21% over the last 12 months.
For the last 50 days, the stock has risen to a peak price of $10.38% and hit a bottom of $42.25%.
The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.
Recently, Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.
On moving volumes measurements, the stock?s 20-Day Simple Moving Average price is $32.83%, 50-Day Simple Moving Average is $26.22% and 200-Day Simple Moving Average is $41.89%.
The stock is now moved 43.33% for the year. Over the last six months it has moved 38.92%, compared with a movement of 21.77% for the quarter, 27.80% for the month and 29.94% for the week.
The average volume, usually a measurement of three months average, is 408.77K. Relative volume on the other hand is 16.27. In total, Aerie Pharmaceuticals, Inc. has 34.21M shares outstanding, with 33.02M of them being free float shares.
The stock?s short float stands at 9.59%, working out to a short ratio of 7.74.
Institutional investors own 98.30% of Aerie Pharmaceuticals, Inc.?s equity, while insiders own 2.20% of the stock. In the last couple of months, the stock has seen -3.41% institutional investor transactions, compared to -4.88% insider transactions.
How have the investors seen their investment in the stock change? Aerie Pharmaceuticals, Inc.’s return on equity for the trailing 12 months is -136.00% and return on investments for a similar period calculates to -%. The company posted return on assets of -47.50% for the same trailing 12 months period.
Does Aerie Pharmaceuticals, Inc. have the ability to keep its doors open ? at least over the short-term? The company’s current ratio at the end of the most recent quarter was 15.50, while quick ratio for the same period was 15.50.
For the matters of debt, the company’s Long Term Debt/Equity for the most recent quarter was 1.47 and Total Debt/Equity for the same period was 1.47.